Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus [Yahoo! Finance]
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: Yahoo! Finance
could support dosing as infrequently as once every three months, plus robust PD (100% inhibition of TSLP-stimulated CCL17 through 20 weeks at 480 mg) and no safety signals or ADA impact. Aclaris has launched randomized, placebo-controlled Phase I-B proof-of-concept trials of ATI-052 in atopic dermatitis and asthma (actively enrolling), with top-line readouts expected in H2 2026 and plans to initiate an asthma Phase IIb in Q4 2026. The company selected oral ATI-2138 for Phase IIb in lichen planus, highlighting its dual ITK (TCR) and JAK3 inhibition as a "bispecific-like" approach; a basket Phase IIb will start with erosive mucosal and cutaneous LP testing 10 mg and 20 mg twice daily, targeting a U.S. market opportunity the company estimates at $1 billion. Interested in Aclaris Therapeutics, Inc.? Here are five stocks we like better. 3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices Aclaris Therapeutics (NASDAQ:ACRS) provided a clinical program update on Tuesday,
Show less
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Aclaris Therapeutics (ACRS) had its "outperform" rating reaffirmed by Wedbush.MarketBeat
- Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript [Seeking Alpha]Seeking Alpha
- Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces Lichen Planus as Lead Indication fAcquire Media Monitor
- Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces Lichen Planus as Lead Indication fGlobeNewswire
- Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026GlobeNewswire
ACRS
Earnings
- 2/26/26 - Miss
ACRS
Sec Filings
- 4/28/26 - Form 8-K
- 4/27/26 - Form 4
- 4/27/26 - Form SCHEDULE
- ACRS's page on the SEC website